Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease - Wikidata - wikimedia - TriplyDB

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease

http://www.wikidata.org/entity/Q34627188

about

CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease Inhibition of microglia activation as a phenotypic assay in early drug discovery CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture.Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.Characterization of a novel adult murine immortalized microglial cell line and its activation by amyloid-beta In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.In vivo TSPO and cannabinoid receptor type 2 availability early in post-stroke neuroinflammation in rats: a positron emission tomography study.New strategies in neuroprotection and neurorepair.Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories.The therapeutic potential of the endocannabinoid system for Alzheimer's disease.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.The influence of cannabinoids on generic traits of neurodegeneration.Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.Cannabinoids: new promising agents in the treatment of neurological diseases.Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses.Cannabinoids in late-onset Alzheimer's disease.New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.Analytical approaches to the diagnosis and treatment of aging and aging-related disease: redox status and proteomics.The role of cannabinoids and leptin in neurological diseases.Mistic and TarCF as fusion protein partners for functional expression of the cannabinoid receptor 2 in Escherichia coli.Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation.Endocannabinoid system in neurodegenerative disorders.Orchestrated activation of mGluR5 and CB1 promotes neuroprotection.Cannabinoid receptor 1 but not 2 mediates macrophage phagocytosis by G(α)i/o /RhoA/ROCK signaling pathway.Microglia and drug-induced plasticity in reward-related neuronal circuits.Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease.

P2860

Q26746050-1F5C550F-556F-40C3-937A-2B475D674F99 Q26750581-B71913C2-610F-490E-9124-AF5F8C3F7D59 Q26767489-F3D5F729-94FB-40FD-A66C-8ECD70F9CA22 Q26783325-2D48003A-C8AC-43BB-99EC-66F96E973014 Q26996061-A1011A71-FD94-4EBE-8B18-0F3410BDE0EA Q27324500-00EAC41E-941C-4427-A628-FF7C8093549D Q30506148-9A6B5539-A557-4FFF-A9F5-45BEAA2B88AF Q33671206-5CAE96E0-576E-4BB2-9D92-AE18AF45DB5F Q34557613-5F9476F4-C92D-4EFE-B3E0-E93E950D902B Q35499568-E33A738E-A147-4830-A9CA-D9784AA99B9A Q35601542-2CF71944-2BE3-4F5D-9112-51350544CE07 Q35863912-70C6E5BC-9D7C-4CB1-9319-E995DE7D93CA Q36077672-43AD773D-3883-4685-A904-C3D046171869 Q36130163-60238ABE-92CC-4D07-9686-E8908B62B514 Q36348374-4F0D7045-D2F0-4650-A8D3-B449B35E66A2 Q36513668-5EC0C94A-9A67-4E83-9462-F65E7C15DE37 Q37622090-F22B365B-5E38-418D-A6DD-9BB28BF5BA93 Q37728661-44E6BD3C-8C65-47AA-B6FB-B957C1BF0A64 Q37921204-103D5A60-106E-4FAE-88B9-25C72F808228 Q37959790-A1BEBD2C-C673-44FA-9EF9-3FFFD1272C59 Q37997020-F6F073B6-D769-466D-9977-BC5A626EB3A0 Q38012845-54DB03A9-8136-4C8E-80AC-B4CBA07594D2 Q38118187-4332EF0E-9F96-43AC-8B57-4FF4F7E54BFE Q38156518-3BF9CEE3-04AB-414A-B33E-12C139EB599D Q38196398-9BEE6834-F99F-4D03-B8FC-2293A25AB31D Q38269376-28D1F1F4-0628-4C71-9425-7CEC4C516AB0 Q38324480-5B5D2DFE-4EB4-4727-A927-F92FE0B8DDA1 Q38383508-19696511-9A33-420C-B382-D6A638F79664 Q38395251-B703A93A-F236-4895-A505-254BAD4E4AB3 Q38396814-C6BC6210-07F6-4DA3-AAB7-A403395A98FA Q38423817-9B8168DD-90E2-46E8-AE04-0BC279FF0A16 Q38540669-9DBA99FD-1E4C-4F77-8418-DB1A2F775CF0 Q38569669-09A73725-2342-4921-B59B-F6835519EFBA Q38748394-BDD91164-8D69-460D-AC26-C6D587F8A0E5 Q38925905-A61945F0-7BB1-4625-8A3A-4B68B8B31727 Q39368845-B3E9B0E8-C736-45CA-A738-EB4D6F258CA9 Q41502987-8D16239B-5790-4A62-8FB2-8AB94A956F9B Q41643613-C71DA79E-6E9E-46DF-AA6E-3F983CB75B5F Q42069199-7CD088B0-CBAD-47F2-89E3-2AF6BF507020 Q46293996-89F9C667-F01D-4469-BCEF-5FABE781A518

P2860

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease

http://www.wikidata.org/entity/Q34627188

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@ast

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@en

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@nl

type

label

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@ast

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@en

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@nl

prefLabel

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@ast

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@en

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@nl

P1433

Q34627188-6F1A2E3B-4F73-4557-AEE4-ADBA51280568

P1476

Q34627188-3F26DF84-80E7-474C-B36B-50D7DA2A7CCD

P2093

Q34627188-1917B03C-7F80-4B2B-9CF5-9C872D0132CD

Q34627188-8355AD41-61EF-4C89-BA9F-C5FCE7F2BC49

Q34627188-AAD2040F-6E6D-446F-92CB-1219354F9D78

P2860

Q34627188-01D5895C-4F2E-4F2C-82BC-A0A94A73E8F1

Q34627188-03DB087E-C646-4A73-8D17-3B2A44B472E8

Q34627188-115CDC8F-21A4-44AF-B850-45CAC54556C0

Q34627188-121D8FD0-A0DE-41E6-A758-E0ABEDB9ED17

Q34627188-122BDCB8-CCB3-4488-9571-BAF669C0CA80

Q34627188-1FFACC41-B68D-4D6D-AD62-A761E1C617F2

Q34627188-22025150-C3F9-4DB5-92A2-B0674F80DA78

Q34627188-351661CF-0C68-450F-8A15-201C7749B947

Q34627188-386AC343-E847-459D-8FEB-D0FD626FFE35

Q34627188-56CE889B-27A7-471B-8D7A-5C3DC01CEDC8

P304

Q34627188-5EEE72F9-19C5-42FC-A7ED-64ADCB771FD8

P31

Q34627188-85134A6F-4E34-4C64-AAC4-3D84573CE0B0

P356

Q34627188-CD79E77D-806B-4382-A8B9-6C21C0DE3161

P433

Q34627188-F62EC6F2-14C4-4386-993F-FB69F28463F3

P478

Q34627188-95339AA0-21EC-46EA-8A09-BAED1D17378C

P50

Q34627188-063EBF7A-FAC6-41FC-880A-4B69349F404D

Q34627188-50F6697B-DD70-4473-8445-3D47937BD9DF

Q34627188-BB250B38-1A16-4257-A1DE-BDAA00FCF839

Q34627188-CD95562D-FE96-4364-A3E6-453CDFAE150A

P577

Q34627188-E10057DF-52E5-4DED-AA49-DF5519A8D350

P5875

Q34627188-E5DE9DAC-0E9E-4B40-BD66-51DBF5E177C1

P698

Q34627188-D346A444-73CD-4FB9-9722-41076DB15DA6

P921

Q34627188-1C2EBDC6-586E-4383-A739-53C413B087D0

Q34627188-26BC0B17-6D90-45A9-8401-F9809E1496AF

Q34627188-DB26AA1A-5A19-4165-B35C-6A5B3AFA6BF9

Q34627188-E5812E86-E61A-451C-96C6-5E63A54F9325

P932

Q34627188-D818A123-E859-4D91-9903-083B2C7E427E

P356

P1433

Molecular Pharmacology

P1476

Cannabidiol and other cannabin ...... levance to Alzheimer's disease

@en

P2093

Ana María Martín-Moreno

http://www.w3.org/2001/XMLSchema#string

Belén G Ramírez

http://www.w3.org/2001/XMLSchema#string

Nadia Innamorato

http://www.w3.org/2001/XMLSchema#string

P2860

125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor

Inflammation and Alzheimer's disease

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor

The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells

The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells

The molecular logic of endocannabinoid signalling

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

Purinergic receptors activating rapid intracellular Ca increases in microglia.

Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain.

P304

964-973

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/MOL.111.071290

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Cuadrado

María L de Ceballos

Raphael Mechoulam

P577

2011-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50196075

http://www.w3.org/2001/XMLSchema#string

P698

21350020

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3102548

http://www.w3.org/2001/XMLSchema#string